Tiered pricing as “emerging market” equals “growth market”

Pharma companies are becoming more adept at selling drugs for different prices in different countries.

“Since 2001 the situation has evolved massively. When we first started, investors didn’t think emerging markets were important. Now there’s an enormous amount of thinking and experimentation by companies, largely as a result of emerging markets being seen as growth markets.”

http://www.ft.com/cms/s/0/c1a2adf4-e770-11e0-9da3-00144feab49a.html

Leave a Reply

Your email address will not be published. Required fields are marked *